141 studies found for:    "AL amyloidosis"
Show Display Options
Rank Status Study
21 Completed A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis
Condition: Primary Amyloidosis
Intervention: Drug: Lenalidomide
22 Not yet recruiting A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
Condition: Amyloidosis
Interventions: Drug: Carfilzomib;   Drug: Thalidomide;   Drug: Dexamethasone
23 Completed Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis
Condition: Amyloidosis
Interventions: Drug: Bortezomib;   Drug: dexamethasone;   Biological: filgrastim;   Procedure: autologous hematopoietic stem cell transplantation (ASCT);   Drug: Melphalan
24 Terminated Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
Condition: Myeloma
Interventions: Drug: Pomalidomide;   Drug: Melphalan;   Drug: Dexamethasone;   Behavioral: Questionnaires
25 Recruiting Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis
Condition: Amyloidosis
Interventions: Other: blood collection;   Other: bone marrow collection
26 Recruiting Oral Doxycycline Administered as an Adjunct to Plasma Cell Directed Therapy in Light Chain Amyloidosis
Condition: Primary Systemic Amyloidosis
Intervention: Drug: Doxycycline
27 Terminated Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis
Condition: Primary Systemic Amyloidosis
Interventions: Drug: 4'-iodo-4'-deoxydoxorubicin;   Other: pharmacological study
28 Completed Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis
Condition: Primary Systemic Amyloidosis (AL)
Interventions: Drug: Melphalan;   Drug: Dexamethasone;   Procedure: Autologous stem cell transplantation
29 Active, not recruiting Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed
Condition: Primary Systemic Amyloidosis
Interventions: Drug: Lenalidomide;   Drug: Cyclophosphamide;   Drug: Dexamethasone
30 Active, not recruiting Study of Oral IXAZOMIB in Adult Patients With Relapsed or Refractory Light Chain Amyloidosis
Condition: Light-Chain Amyloidosis
Intervention: Drug: MLN9708
31 Completed
Has Results
Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis
Condition: Primary Systemic Amyloidosis
Interventions: Drug: bortezomib;   Drug: cyclophosphamide;   Drug: dexamethasone
32 Not yet recruiting Treatment of AL Amyloidosis
Condition: Amyloidosis
Intervention: Drug: Daratumumab
33 Recruiting A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early
Conditions: Plasma Cell Dyscrasia;   Monoclonal Gammopathy
Intervention:
34 Completed A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
Conditions: Leukemia;   Amyloidosis
Interventions: Drug: Lenalidomide;   Drug: Melphalan;   Drug: Dexamethasone
35 Recruiting Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Condition: Amyloidosis
Intervention: Drug: Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4
36 Completed Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis
Condition: Amyloidosis
Interventions: Drug: cyclophosphamide;   Drug: lenalidomide;   Drug: dexamethasone
37 Active, not recruiting Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
Conditions: Light Chain Deposition Disease (LCDD or MIDD);   Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD);   Monoclonal Immunoglobulin Deposition Disease (MIDD);   Amyloidosis
Intervention: Drug: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
38 Completed S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma
Interventions: Biological: recombinant interferon alfa;   Drug: dexamethasone
39 Completed CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: lenalidomide
40 Completed Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: lenalidomide;   Drug: melphalan

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years